Bellicum Pharmaceuticals Statistics
Share Statistics
Bellicum Pharmaceuticals has 10.41M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 10.41M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,448 |
| FTD / Avg. Volume | 15.56% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.89 and the forward
PE ratio is null.
Bellicum Pharmaceuticals's PEG ratio is
0.37.
| PE Ratio | -0.89 |
| Forward PE | n/a |
| PS Ratio | 14.8 |
| Forward PS | n/a |
| PB Ratio | 11.02 |
| P/FCF Ratio | -0.86 |
| PEG Ratio | 0.37 |
Financial Ratio HistoryEnterprise Valuation
Bellicum Pharmaceuticals has an Enterprise Value (EV) of 359.34K.
| EV / Sales | 0.24 |
| EV / EBITDA | -0.01 |
| EV / EBIT | -0.01 |
| EV / FCF | -0.01 |
Financial Position
The company has a current ratio of 6.31,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.31 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -586543.48 |
Financial Efficiency
Return on Equity is -1239.35% and Return on Invested Capital is -1339.11%.
| Return on Equity | -1239.35% |
| Return on Assets | -104.83% |
| Return on Invested Capital | -1339.11% |
| Revenue Per Employee | $115,384.62 |
| Profits Per Employee | $-1,921,000 |
| Employee Count | 13 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -6.35% in the
last 52 weeks. The beta is 1.38, so Bellicum Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -6.35% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.29 |
| Relative Strength Index (RSI) | 40.84 |
| Average Volume (20 Days) | 28,581 |
Income Statement
In the last 12 months, Bellicum Pharmaceuticals had revenue of 1.5M
and earned -24.97M
in profits. Earnings per share was -0.81.
| Revenue | 1.5M |
| Gross Profit | 1.5M |
| Operating Income | -26.98M |
| Net Income | -24.97M |
| EBITDA | -26.98M |
| EBIT | -24.97M |
| Earnings Per Share (EPS) | -0.81 |
Full Income StatementBalance Sheet
The company has 21.84M in cash and 0 in
debt, giving a net cash position of 21.84M.
| Cash & Cash Equivalents | 21.84M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -575.42M |
| Total Assets | 6.85M |
| Working Capital | 4.6M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -25.78M
and capital expenditures -21K, giving a free cash flow of -25.8M.
| Operating Cash Flow | -25.78M |
| Capital Expenditures | -21K |
| Free Cash Flow | -25.8M |
| FCF Per Share | -0.84 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -1798.73% and -1664.87%.
| Gross Margin | 100% |
| Operating Margin | -1798.73% |
| Pretax Margin | -1664.73% |
| Profit Margin | -1664.87% |
| EBITDA Margin | -1798.73% |
| EBIT Margin | -1798.73% |
| FCF Margin | -1720.27% |
